Literature DB >> 3918662

Hyperlipidaemia.

L E Murchison.   

Abstract

Mesh：

Substances：

Year:  1985        PMID： 3918662      PMCID： PMC1418051          DOI： 10.1136/bmj.290.6467.535

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  3 in total

1.  A new diagnostic method in allergic disease.

Authors:  A P BLACK
Journal:  Pediatrics       Date:  1956-05       Impact factor: 7.124

2.  Frequency of risk factors for ischaemic heart-disease in a healthy British population. With particular reference to serum-lipoprotein levels.

Authors:  B Lewis; A Chait; I D Wootton; C M Oakley; D M Krikler; G Sigurdsson; A February; B Maurer; J Birkhead
Journal:  Lancet       Date:  1974-02-02       Impact factor: 79.321

Review 3.  Classification of hyperlipidaemias and hyperlipoproteinaemias.

Authors:  J L Beaumont; L A Carlson; G R Cooper; Z Fejfar; D S Fredrickson; T Strasser
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408
  3 in total
  3 in total

Review 1.  Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.

Authors:  J A Balfour; D McTavish; R C Heel
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

Review 2.  Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia.

Authors:  P A Todd; A Ward
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

Review 3.  Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.

Authors:  J P Monk; P A Todd
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.